Rebalancing metal dyshomeostasis for Alzheimer's disease therapy

被引：30

作者：

Yang, Guan-Jun ^{[1
]}

Liu, Hao ^{[2
]}

Ma, Dik-Lung ^{[2
]}

Leung, Chung-Hang ^{[1
]}

机构：

[1] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa 999078, Macao, Peoples R China

[2] Hong Kong Baptist Univ, Dept Chem, Kowloon, Hong Kong 999077, Peoples R China

来源：

JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY | 2019年 / 24卷 / 08期

基金：

中国国家自然科学基金;

关键词：

Metal dyshomeostasis; Metal ions; Alzheimer's disease; Metal chelators; A beta aggregation inhibitors; Multifunctional agents; BLOOD-BRAIN-BARRIER; A-BETA AGGREGATION; AMYLOID-BETA; MITOCHONDRIAL DYSFUNCTION; SECONDARY PREVENTION; OXIDATIVE STRESS; ION HOMEOSTASIS; BINDING SITE; COPPER; TAU;

D O I：

10.1007/s00775-019-01712-y

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Alzheimer's disease (AD) is a type of neurodegenerative malady that is associated with the accumulation of amyloid plaques. Metal ions are critical for the development and upkeep of brain activity, but metal dyshomeostasis can contribute to the development of neurodegenerative diseases, including AD. This review highlights the association between metal dyshomeostasis and AD pathology, the feasibility of rebalancing metal homeostasis as a therapeutic strategy for AD, and a survey of current drugs that action via rebalancing metal homeostasis. Finally, we discuss the challenges that should be overcome by researchers in the future to enable the practical use of metal homeostasis rebalancing agents for clinical application.

引用

页码：1159 / 1170

页数：12

共 50 条

[21] Calcium dyshomeostasis in the course of disease in individual patients with Alzheimer's dementia
Rípová, D
Platilová, V
Jirák, R
NEW TRENDS IN ALZHEIMER AND PARKINSON RELATED DISORDERS, 2003, : 53 - 56
[22] Metal Dyshomeostasis and Inflammation in Alzheimer's and Parkinson's Diseases: Possible Impact of Environmental Exposures
Myhre, Oddvar
Utkilen, Hans
Duale, Nur
Brunborg, Gunnar
Hofer, Tim
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2013, 2013
[23] Challenges Associated with Metal Chelation Therapy in Alzheimer's Disease
Hegde, Muralidhar L.
Bharathi, P.
Suram, Anitha
Venugopal, Chitra
Jagannathan, Ramya
Poddar, Pankaj
Srinivas, Pullabhatla
Sambamurti, Kumar
Rao, Kosagisharaf Jagannatha
Scancar, Janez
Messori, Luigi
Zecca, Luigi
Zatta, Paolo
JOURNAL OF ALZHEIMERS DISEASE, 2009, 17 (03) : 457 - 468
[24] APP dyshomeostasis in the pathogenesis of Alzheimer's disease: implications for current drug targets
Sirisi, Sonia
Sanchez-Aced, Erika
Belbin, Olivia
Lleo, Alberto
ALZHEIMERS RESEARCH & THERAPY, 2024, 16 (01)
[25] Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimer's Disease
Sternberg, Zohara
Hu, Zihua
Sternberg, Daniel
Waseh, Shayan
Quinn, Joseph F.
Wild, Katharine
Kaye, Jeffrey
Zhao, Lin
Garrick, Michael
AGING AND DISEASE, 2017, 8 (02): : 215 - 227
[26] Copper dyshomeostasis in Wilson disease and Alzheimer's disease as shown by serum and urine copper indicators
Squitti, Rosanna
Ghidoni, Roberta
Simonelli, Ilaria
Ivanova, Irena D.
Colabufo, Nicola Antonio
Zuin, Massimo
Benussi, Luisa
Binetti, Giuliano
Cassetta, Emanuele
Rongioletti, Mauro
Siotto, Mariacristina
JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2018, 45 : 181 - 188
[27] Metal chelation therapy for Alzheimer disease
Rosenberg, RN
ARCHIVES OF NEUROLOGY, 2003, 60 (12) : 1678 - 1679
[28] Linking activity dyshomeostasis and sleep disturbances in Alzheimer disease
Slutsky, Inna
NATURE REVIEWS NEUROSCIENCE, 2024, 25 (04) : 272 - 284
[29] Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease
Velazquez, Ramon
Tran, An
Ishimwe, Egide
Denner, Larry
Dave, Nikhil
Oddo, Salvatore
Dineley, Kelly T.
NEUROBIOLOGY OF AGING, 2017, 58 : 1 - 13
[30] Transition metal chelator therapy - A potential treatment for Alzheimer's disease?
Gnjec, A
Fonte, JA
Atwood, C
Martins, RN
FRONTIERS IN BIOSCIENCE, 2002, 7 : D1016 - D1023

← 1 2 3 4 5 →